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Editorial for Translational Andrology and Urology regarding: 20 
Isolated Red Patches Seen During Endoscopic Surveillance of Bladder Cancer: Incidence of 21 
Malignancy and When Should We Biopsy? 22 
Nkwam N et al. J Endourol. 2018 Feb 1. doi: 10.1089/end.2017.0744 23 
 24 
The causes of “red patches” (RPs) in the bladder are many and varied, ranging from minor 25 
cystoscope trauma and inflammatory lesions to carcinoma in situ (CIS). The diagnosis of the latter is 26 
crucial since CIS is a highly malignant lesion both molecularly and clinically [1], and is the single most 27 
important risk factor for progression to muscle-invasive disease in the EORTC non-muscle-invasive 28 
bladder cancer (NMIBC) risk tables [2]. Thus, in the context of NMIBC, urologists face a dilemma 29 
when red patches are observed during endoscopic surveillance: to biopsy or not to biopsy. This 30 
dilemma is magnified when one considers that previous data show a pick-up rate for malignancy of 31 
only 11.9% (although CIS was diagnosed in 78.3% of these malignant biopsies) [3], and that in the 32 
presence of concomitant tumour, there is a risk of tumour cell reimplantation at the biopsy site [4], 33 
thus potentially augmenting the risk of multifocal disease. Notwithstanding, the EAU guidelines for 34 
NMIBC recommend taking cold-cup biopsies from abnormal urothelium identified during 35 
transurethral resection (TURBT) [5]; the use of intravesical chemotherapy mitigates the potential risk 36 
of tumour cell reimplantation [6]. However, in the flexible cystoscopy surveillance setting the 37 
dilemma remains. 38 
 39 
In a study recently published in the Journal of Endourology, Nkwam et al retrospectively reviewed 40 
4,805 white light imaging (WLI) flexible cystoscopy reports to identify 241 episodes where solitary 41 
RPs had been identified in 183 NMIBC surveillance patients; 120 such RP episodes (49.8%) occurred 42 
in patients previously-treated with intravesical BCG [7]. Overall, 85 RPs (35.3%) were biopsied, and 43 
malignancy was found in 20 biopsies (23.5%). All positive biopsies were identified in patients 44 
previously-diagnosed with intermediate- or high-risk NMIBC; no low-risk NMIBC surveillance 45 
patients, nor patients under the age of 67 years, had malignant histology following the biopsy of a 46 
RP. Importantly, 11 of the 20 malignant biopsies (55%, or 12.9% of all RPs biopsied) diagnosed CIS. 47 
Biopsies were undertaken by rigid cystoscopy under general/regional anaesthesia on 53 occasions 48 
(62.4%), and immediately at flexible cystoscopy on 32 occasions (37.6%). In the former, urothelial 49 
carcinoma (UC) and CIS were identified in 30.4% of biopsies, and for the latter in 18.8% of biopsies. It 50 
would be interesting to know if there was a department policy in determining the method of biopsy; 51 
for example, did prior intravesical BCG treatment or prior negative flexible cystoscopy biopsy 52 
increase the likelihood of biopsy by rigid cystoscopy? Or was rigid cystoscopy routine as first follow-53 
up after BCG treatment for CIS, whereas flexible cystoscopy was undertaken later in the surveillance 54 
of recurrence-free patients where the likelihood of CIS per se was lower? Furthermore, urine 55 
cytology was not undertaken in any patient, as per the unit’s policy; this is understandable, since the 56 
benefit of routine urine cytology is questionable [8;9], but it would have been informative to observe 57 
the relationship between malignant RPs and abnormal urine cytology. Other units operate a similar 58 
policy, but still collect a whole void urine sample pre-cystoscopy and subsequently request urine 59 
cytology if suspicious findings emerge from the cystoscopy (if not, the sample is disposed of). In 60 
intermediate- and high-risk NMIBC patients one should always be aware that the source of abnormal 61 
or malignant cytology could be WLI-invisible CIS or upper tract urothelial carcinoma (UTUC). In the 62 
future, DNA-based urine tests may improve diagnosis [10].  63 
 64 
However, the comparison of the yield of malignant disease between rigid and flexible cystoscopic 65 
biopsy of RPs is probably the most interesting aspect of the study, with almost double the yield of 66 
malignant disease with rigid cystoscopic biopsy. The interpretation of the small biopsies achievable 67 
with flexible cystoscopes is challenging for histopathologists and so these findings are not 68 
unexpected, and there are inherent risks to spontaneous outpatient bladder biopsies due to the 69 
prevalence of concurrent diseases and antiplatelet or anticoagulant medication in the predominantly 70 
elderly UC population. Thus, in the WLI setting, should one surmise that RPs should only be biopsied 71 
electively by rigid cystoscopy in the operating theatre? As a counterpoint, in Nkwam et al’s study 72 
some NMIBC patients with RPs were scheduled for earlier follow-up flexible cystoscopy (4-6 weeks 73 
later) if biopsy was not undertaken; some of these patients did not undergo biopsy at this episode 74 
either, others did not return, and some no longer had an identifiable RP [7]. There is thus potential 75 
value in all patients with RPs being biopsied when the RP is first seen in the outpatient clinic.  76 
 77 
Importantly, urologists now have access to optical image enhancement technologies (e.g. narrow 78 
band imaging, NBI, and photodynamic diagnosis, PDD, etc [11]). In the TURBT setting, evidence 79 
suggests that NBI and PDD are more sensitive than WLI for detecting CIS [12;13]. However, in the 80 
outpatient flexible cystoscopy setting, does the enhanced optical diagnosis of CIS by NBI or PDD 81 
outweigh the shortcomings of the small biopsy? Limited data would suggest that biopsies obtained 82 
during PDD-guided flexible cystoscopy are adequate for the diagnosis of Ta, T1a and CIS in 90-97% of 83 
cases [14;15]. Notwithstanding, the use of PDD in the surveillance setting with outpatient flexible 84 
cystoscopy is sparsely investigated. Feasibility studies have been successful [14], but the clinical 85 
relevance and benefits have not yet been thoroughly investigated. An ongoing Danish randomised 86 
controlled trial is currently investigating PDD-guided flexible cystoscopy NMIBC surveillance in the 87 
outpatient setting (DaBlaCa11) [abstract 1140 EAU2018], and the results are eagerly awaited. 88 
However, there are a number of potential limitations to PDD (e.g. catheterisation and instillation of 89 
the PDD agent, photo-bleaching and time limitations, inter-surgeon variability, cost, etc) that may 90 
mean its adoption in the outpatient setting is restricted to specialised centres or centres with a 91 
specific interest in PDD. NBI does not possess the same limitations, and its adoption in the 92 
outpatient NMIBC surveillance setting has been more rapid [16]. Furthermore, the utilisation of high 93 
definition (HD) cameras also appears to improve the diagnosis of abnormal lesions when compared 94 
to standard definition (SD) [17].  95 
 96 
In summary, Nkwam et al have demonstrated that the incidence of malignancy in RPs identified 97 
during NMIBC surveillance in their study is higher than previously described, 23.5% [7] vs. 11.9% [3]. 98 
Could the use of HD WLI in the more recent study partly explain this considerable difference? The 99 
use of HD or SD is not specified in the publication. Malignancy was only identified in patients with 100 
previous intermediate- or high-risk NMIBC and in patients 67 years or older; the diagnosis of 101 
malignancy was considerably higher if biopsy was undertaken by rigid cystoscopy in the operating 102 
theatre (30.4% vs 18.8%). Other studies would suggest that if image enhancement technologies 103 
were to be used, then the diagnosis of malignancy from a suspicious RP would be higher [12;13], and 104 
that adequate biopsies can be obtained at flexible cystoscopy [14;15]. Thus, should we now 105 
conclude that when RPs are identified by WLI flexible cystoscopy in intermediate- and high-risk 106 
NMIBC surveillance patients then they should be biopsied by rigid cystoscopy in the operating 107 
theatre, but if PDD or NBI flexible cystoscopy are utilised then outpatient biopsy is appropriate and 108 
adequate? In favour of flexible cystoscopic biopsy is the omission of the time and cost of general or 109 
regional anaesthesia, especially if the patient has RPs and no tumour whereby, in the absence of a 110 
malignant cause, the RPs might have disappeared at the time of rigid cystoscopy. One can only 111 
recommend that urologists discuss the utility of flexible cystoscopy biopsies with their 112 
histopathology colleagues to reach a consensus on a unit-by-unit basis, and dependent upon the 113 
local availability of PDD or NBI.  114 
  115 
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